ADB-4en-PINACA is a cannabinoid designer drug that has been found as an ingredient in some synthetic cannabis products, first appearing in early 2021. It is a reasonably potent cannabinoid agonist in vitro but has not been so widely sold as related compounds such as ADB-PINACA and MDMB-4en-PINACA.

Legality

In the United States, the DEA has filed a notice for its intent to temporarily place ADB-4en-PINACA into Schedule I status starting on or after May 4th, 2023 for up to 2 years, during which it's possible the DEA could file for permanent scheduling within those 2 years. If it's filed on May 4, 2023, and the DEA does not file to permanent placement the temporary Schedule I order will expire on May 4, 2025.

ADB-4en-PINACA

See also

5F-ADB-PINACA

ADB-BINACA

ADB-CHMINACA

ADB-FUBINACA

ADB-HEXINACA

References

Cannabinoids

Designer drugs

Indazolecarboxamides

Tert-butyl compounds

ADB-4en-PINACA